{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:38:51Z","timestamp":1761975531296,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaip.2020.06.037","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T19:27:28Z","timestamp":1593286048000},"page":"3605-3607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrence of eosinophilic inflammation and worsening asthma symptoms between doses of benralizumab"],"prefix":"10.1016","volume":"8","author":[{"given":"Maxime","family":"Cormier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Cartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.06.037_bib1","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2020.06.037_bib2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.anai.2019.02.016","article-title":"Rapid onset of effect of benralizumab on morning peak expiratory flow in\u00a0severe, uncontrolled asthma","volume":"122","author":"Chupp","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.06.037_bib3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12325-018-0727-8","article-title":"Rapid and consistent improvements in morning PEF in patients with severe eosinophilic asthma treated with mepolizumab","volume":"35","author":"Ortega","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2020.06.037_bib4","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2020.06.037_bib5","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.06.037_bib6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaip.2019.08.005","article-title":"Secondary loss of response to mepolizumab in severe eosinophilic asthma","volume":"8","author":"Cormier","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.06.037_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.06.037_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/17476348.2020.1718495","article-title":"Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab","volume":"14","author":"Hillas","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaip.2020.06.037_bib9","doi-asserted-by":"crossref","first-page":"1802248","DOI":"10.1183\/13993003.02248-2018","article-title":"Severe asthma with blood hypereosinophilia associated with JAK2 V617F mutation: a case series","volume":"53","author":"Tabeze","year":"2019","journal-title":"Eur Respir J"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820306723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820306723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:28:27Z","timestamp":1761974907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820306723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2213219820306723"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.06.037","relation":{},"ISSN":["2213-2198"],"issn-type":[{"type":"print","value":"2213-2198"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrence of eosinophilic inflammation and worsening asthma symptoms between doses of benralizumab","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}